

Pride in family medicine: Gender affirming care

PANELISTS

Dr. Rahima Alani • Dr. Carrie Bernard

WITH

Dr. Stephanie Zhou • Dr. Nikki Bozinoff





Please introduce yourself in the chat!



@OntarioCollege
#PractisingWell

Your Panelists: Disclosures

Dr. Rahima Alana

Relationships with financial sponsors (including honoraria):

- OCFP Practising Well CoP Speaker
- Organon (previously Merck) Honoraria (speaker/clinical trainer)
- Reya Health Medical Advisor

Dr. Carrie Bernard

Relationships with financial sponsors (including honoraria):

- OCFP- Practising Well Scientific Planning Committee
- OCFP Practising Well CoP Speaker
- University of Toronto Stipend to supervise learners (students and residents) for the Department of Family and Community Medicine
- University of Toronto Stipend for role in the Division of Mental Health and Addictions
- McMaster University –Stipend to supervise residents
- College of Family Physicians of Canada Board Member

Disclosures

Dr. Nikki Bozinoff @NikkiBozinoff

Relationships with financial sponsors (including honoraria):

- Ontario College of Family Physicians Practising Well Implementation Group Member, CoP Speaker
- CAMH
- Department of Family and Community Medicine (University of Toronto)
- National Institute on Drug Abuse
- Womenmind
- CIHR
- Academic Health Sciences Alternate Payment Plan

Dr. Stephanie Zhou @stephanieyzhou

Relationships with financial sponsors (including honoraria):

- Ontario College of Family Physicians Practising Well Scientific Planning Committee
- Canadian Medical Association Honoraria for practice management lectures
- Habitat for Humanity GTA Board of Directors member
- Toronto Public Health Board of Directors member

Disclosure of Financial Support

This program has received funding from the Ontario Ministry of Health and in-kind support from the Ontario College of Family Physicians and the Department of Family and Community Medicine, University of Toronto.

Potential for conflict(s) of interest: N/A

Mitigating Potential Bias


- The Scientific Planning Committee (SPC) has control over the choice of topics and speakers.
- Content has been developed according to the standards and expectations of the Mainpro+ certification program.
- The program content was reviewed by the SPC.

Land Acknowledgement

We acknowledge that the lands on which we are hosting this meeting include the traditional territories of many nations.

The OCFP and DFCM recognizes that the many injustices experienced by the Indigenous Peoples of what we now call Canada continue to affect their health and well-being. The OCFP and DFCM respects that Indigenous people have rich cultural and traditional practices that have been known to improve health outcomes.


I invite all of us to reflect on the territories you are calling in from as we commit ourselves to gaining knowledge; forging a new, culturally safe relationship; and contributing to reconciliation.



Pride in family medicine: Gender affirming care

You raised important questions we'll try to work through together today:

- What can I do as a general practitioner with little time or training in this field?
- How to assess starting gender supporting hormones in teens and adults?
- How to diagnose eligibility for hormonal therapy? Navigating how to apply for surgery?
- How to use respectful language when addressing patients?



Pride in family medicine: Gender affirming care

Your Panelists

Dr. Carrie Bernard

Brampton, ON

Dr. Rahima Alani

Scarborough, ON

Creating a safe gender-affirming space for your patient

OCFP Practicing Well, Community of Practice
June 26, 2024

Why?????



Barriers to accessing gender-affirming health care

- 45% of trans and non-binary people had a past-year unmet health care need, compared to 4% of the general population (Trans Pulse, 2020)
- 12% of individuals avoided the ER because of fear of mistreatment in the past year (Trans PULSE Canada National Survey 2019)
- Nearly half of older youth (47%) and one third of younger youth (33%)
 had not received physical healthcare they needed at some point during
 the last year (Being Safe, Being Me: Canadian Trans Youth Health
 Survey, 2019)
- 50% of trans people have had to teach their medical providers about being trans (National Transgender Discrimination Survey, 2016)

Learning the language: Definitions

- Cis: Having a non-trans gender identity.
- Trans: Trans refers to a state of incongruence of one's gender identity with the gender assigned at birth.
- Non-binary: Umbrella term for anyone who does not identify with static, binary gender identities.
- **Two-Spirit**: An umbrella term describing the diversity of gender expressions and sexual orientations present in traditional belief systems held by North American First Nations persons
- AFAB: Assigned Female at Birth
- AMAB: Assigned Male at Birth
- **Gender Dysphoria**: May refer specifically to the DSM-5 diagnosis and/or to the experience of distress associated with having one's current gender presentation misaligned with their internal gender identity
- **Gender Incongruence**: May refer specifically to the WHO ICD-11 diagnosis and/or to the experience of having one's internal identity misaligned with their sex assigned at birth.


The Genderbread Person v3.3

Gender is one of those things everyone thinks they understand, but most people don't. Like *Inception*. Gender isn't binary. It's not either/or. In many cases it's both/and. A bit of this, a dash of that. This tasty little guide is meant to be an appetizer for gender understanding. It's okay if you're hungry for more. In fact, that's the idea.



In each grouping, circle all that apply to you and plot a point, depicting the aspects of gender toward which you experience attraction.

4 (of infinite) possible




Making your space "safe"

Safe Language

- "My pronouns are she and her today. If that changes, I will tell you"
- "What pronouns are you using today? If that changes, please let me know"
- "What is your authentic name? Where is it safe to use it?"
 - i.e. waiting room, when I leave a message, etc.
- Misgendering:
- Apologize, correct error and move on...
- Avoid gender-based assumptions; the gender binary
- Avoid heterosexist assumptions
- If in doubt, use gender neutral language

Safe Language


Body Parts and Language



Safe Language

LGBTQ Inclusive Language

In The Workplace



Maternity and paternity leave

Husband, wife, boyfriend, girlfriend

"What are your preferred pronouns?"

Ms., Mr., or Mrs.

Mailman, chairman, policeman

Sexual preference



Colleagues, team, people

Parental leave, parental time off

Partner, spouse

"What pronouns do you use?"

People's first names, non-gender specific titles like Mx or M

Mail clerk, chairperson, police officer

Sexual orientation



Creating a gender-diverse positive environment

- Gender neutral bathrooms
- Pride flags or other 2SLGBTQ+ posters
- Create and display a gender diversity policy statement
 - https://www.ontariomidwives.ca/diversity equity-inclusion
- Consider requesting training for you and your staff and team to increase internal capacity to provide transaffirming and trans-inclusive care
 - https://www.rainbowhealthontario.ca/trans health connection/



Now that it's safe, what can YOU do?

Primary care...do what you do best!

- Remember, trans and gender diverse patients most often seek medical care for non-gender identity issues
 - You do not have to talk about gender issues if patient comes for URI, MSK injury etc.
- Gender identity issues may play important role in mental health concerns
 - This population has significantly higher proportion of mental health issues, especially if unable to access gender-affirming care or has lack of support in their gender journey
- Preventative care:
 - For cis patients; screen for organs present
 - For trans patients: screen for organs present

If you want to learn more

- Access resources through Rainbow Health
- Review the Sherborne Health Centre Interactive Trans Health Guide
- Join the Ontario wide mentorship calls
- Realize that you already prescribe hormones every day...you can manage the follow up prescriptions if you are not yet ready to start a new prescription



Pride in family medicine: Gender affirming care

Your Panelists

Dr. Carrie Bernard

Brampton, ON


Dr. Rahima Alani

Scarborough, ON

WHY THIS TOPIC IS IMPORTANT (TO ME)

- •One in 300 people in Canada aged 15 and older are transgender or non-binary.1
- •Among Canadian transgender youth, 77% had a primary care provider and yet 47% reported a past-year unmet health need.²
- •In a Canadian study of transgender adolescents, **65**% **reported suicidal ideation** in the past year (5x the rate of their cisgender peers); **trans youth 19-25 have 16x the risk of a suicide attempt** in the past year.³

HOW CAN WE SUPPORT OUR PATIENTS?





UPCOMING COURSES

For more information on upcoming courses or to register, visit

<u>learn.rainbowhealthontario.ca</u>

Click here to register

Always Available: 2SLGBTQ Foundations Course in English and French	~
Always Available: 2SLGBTQ Older Adults and Inclusive Care	~
June 5, July 10: Removing the Barriers: Making your Organization 2SLGBTQ friendly	~
June 10: Trans 101 – Adults and Older Adults	~



June 12: Transition-related Hormone Therapy in Primary Health Care	~
June 18, July 24: 2SLGBTQ Trauma Informed Care	~
June 19: Trans 101 – Transitioning	~
July 15, July 18: 2SLGBTQ Emotional and Mental Health *NEW*	~
July 4: Masculinizing Surgeries: Post-Operative Complications in Primary Health Care	~
Vaginoplasty: Post-Operative Complications in Primary Health Care	~
Transition-related Surgeries: Planning, Referral, and Care	~

4th edition: sherbourne's guidelines for gender-affirming primary care with trans and non-binary patients

https://www.rainbowhealthontario.ca/product /4th-edition-sherbournes-guidelines-forgender-affirming-primary-care-with-transand-non-binary-patients/




Table of Contents

Possible questions to explore gender identity and expression

ender-affirming anning visits3

Discontinuation of hormone therapy... Referrals and advocacy in support of

Acknowledgements.....

Table 2 Options

Table 6 Table Recommended bloodwork for monitoring feminizing hormone therapy

Reco In this table, smaller and lighter grey "x"s indicate parameters that are measured under particular circumstances

) 30	
f-determined, based	
wledge32	
cation and	

ith transition-

..28

4th	
gen	
non	
	Spironol (oral)
<u>http</u>	
<u>/4tl</u>	Cyprote
gen	(oral)
and	
	"Rarely Use d

SPIRONOLACTONE
CYPROTERONE

Price : repres Prices

Note: For pa

Test	Baseline	4–6 weeks	3 months	6 months	12 months°	Yearly	According to guidelines for cis patients, or provider discretion	nths	one therapy
							provider discretion	asis)	
CBC ³	Х		×	х	х	×			2 course
ALT/AST ^o	х		х	х	x	x	x		rolder
Creatinine/lytes ^c	х	x	х	×	х	×			stments
Hba1c or fasting glucose	х				x		x		ation with nitigation and
Lipid profile	х				х		×		
Total testosterone	х		х	х	х	х		n, low	
Estradiol	х		х	х	х	Х		cts	ormone therapy
Prolactin ^d	Х				x	×	×	am	for older
Other	Нер В, С							\ST/ALT,	ljustments tigation with
	Consider: H				ening as			stosterone, glucose	mitigation and
								oalc, lipid e, +/-Cr, lytes ^d	

4th edition: sherbourne's guidelines for gender-affirming primary care with trans and non-binary patients

https://www.rainbowhealthontario.ca/product/ /4th-edition-sherbournes-guidelines-forgender-affirming-primary-care-with-transand-non-binary-patients/

APPENDIX P:

Template Letter in Support of an Application For Change of Sex Designation on an Ontario Birth Registration

Note:	 The letter must be from a physician, psychologist, or psychological associate authorized to practice in Canada and must be on the medical professional or clinic's letterhead providing an address and phone number
_	Patient must submit an original (not photocopy) signed in blue ink by the provider.
Date:	
To: SE	RVICE ONTARIO, THE OFFICE OF THE REGISTRAR GENERAL
Re: Ap	plication by (
I am a	eracticing member in good standing with the
	specify the appropriate regulatory body
Licens	No:
I have r	provided medical/psychological support and treatment to the applicant, (
WIIO IS	requesting a change in gender designation from
	n that the applicant's gender identity does not accord with the gender designation on the applicant's birth registration
and I a	n of the opinion that the change of gender designation on the birth registration is appropriate.
Yours t	uly,
	signature and name of provider

4th edition: sherbourne's guidelines for gender-affirming primary care with trans and non-binary patients

https://www.rainbowhealthontario.ca/product/4th-edition-sherbournes-guidelines-for-gender-affirming-primary-care-with-trans-and-non-binary-patients/

APPENDIX N:


Sample Request for an Unlisted Drug Product, Testosterone Enanthate (Delatestryl)

- 0		iO Ministry of Health Exceptional Access Pri 5700 Yonge Street 3 st Toronto ON M2M 4KS		3 rd floor	Request for an Unlisted Drug Product Exceptional Access Program (EAP)				
Please fax completed form and/or any additional relevant information to 416 327–7526 or toll-free 1 856 811–8903; or send to Exceptional Access Program Branch (EAPB), 3 rd floor, 5700 Yonge Street, Toronto ON M2M 4KS. For copies of this and other EAP forms, please visit http://www.health.gov.on.ca/english/public/forms/form_menus/odb_fm.html									
The Ministry of Ontario Drug &	Health and Long-	Term Care (the "min	istry") conside	ers requests for oo	verage of drug product			t Formulary under Section 16 of the ddfional documentation to support	
equost. Yease onsuro	that all appropriate	information for eac	h section is p	rovided to avoid d	elays.				
Section 1	- Prescribe	r Information			Section 2	2 - Patient Info	mation		
irst name		Initial	Last name		First name		Initial	Last name	
ample					sample				
failing Addr Street no.	Street name				Health Num	ber			
Яty				Postal code					
ax no.			Telephone	e no.	Date of birth	(jaggolmmylald)			
)			()					
New red	quest	Rer	newal of ex	isting EAP app	roval (specify EAPt	0		_	
section 3	- Drug Requ								
dequested d							DIN		
	e Enanthate (I	DelatestryI)					00029246		
Strength / Do						administration			
200 mg/mL						y require adjustm	ent		
expected sta	art date				Duration of th	erapy			
Postles 4	Biannasia				indetinite	indefinite			
		and Reason	for Use						
Diagnosis for	r which the drug		for Use						
Nagnosis for Gender Dys	r which the drug sphoria	is requested:	for Use						
Diagnosis for Gender Dyr Resson for u	r which the drug sphoria se over formular	is requested: ry alternatives:		stosterone En	inthate and Testosi	terone Cypionate.	due to risk o	of backorder	
Diagnosis for Gender Dys Reason for u No alternat	r which the drug sphoria are over formular tive on formula	is requested: ry alternatives: ry, needs EAP f	or both Te		unthate and Testosi t date & objective ev			of backorder	
Diagnosis for Gender Dys Reason for u No alternati I the patient	r which the drug sphoria se over formular tive on formula is currently takin	is requested: ry alternatives: ry, needs EAP f	for both Te	sse provide star				of backonder	
Diagnosis for Gender Dys Reason for u No alternati I the patient	r which the drug sphoria se over formular tive on formula is currently takin	is requested: ry alternatives: ry, needs EAP f ng the requested p	for both Te	sse provide star				of backonder	
Nagnosis for Gender Dyn Basson for u No alternat I the patient If applicable Section 5	r which the drug sphoria se over formular tive on formula is currently takin e: improved me	is requested: ry alternatives: ry, needs EAP f rg the requested p mtal health and nd / or Previo	for both Te product, ples psychosoci us Medic	se provide star ial function.	t date & objective ev	idence of its efficac		of backorder	
Nagnosis for Bender Dyn Basson for u No alternat I the patient I applicable Section 5	r which the drug sphoria se over formular tive on formula is currently takin e: improved mo — Currentl an provide details of	is requested: ry alternatives: ry, needs EAP f ng the requested p mtal health and ad f or Previo f alternatives (list	for both Te product, ples psychosoci us Medic	se provide star ial function.	t date & objective ev henepy) tried for this	idence of its efficacy		of backorder	
Nagnosis for Gender Dys Reason for u No alternati I the patient If applicable Section 5 a) Please;	r which the drug sphoria se over formula is currently takin e: improved me — Current ar provide details o Name	is requested: ry alternatives: ry, needs EAP f rg the requested p mtal health and ed f or Previo f alternatives plat of drug	for both Te product, plea psychosoci us Medic ad drugs are	se provide star ial function.	t date & objective ev	condition:	r.	of backorder	
Nagnosis for Gender Dys Reason for u No alternati I the patient If applicable Section 5 a) Please;	r which the drug sphoria se over formula is currently takin e: improved me — Current ar provide details o Name	is requested: ry alternatives: ry, needs EAP f ng the requested p mtal health and ad f or Previo f alternatives (list	for both Te product, plea psychosoci us Modic ad drugs are	ese provide startial function. ENIONE d'or non-drug M	t date & objective ev henepy) tried for this	condition:	r.		
Nagnosis for Gender Dys Reason for u No alternati I the patient If applicable Section 5 a) Please;	r which the drug sphoria se over formula is currently takin e: improved me — Current ar provide details o Name	is requested: ry alternatives: ry, needs EAP f rg the requested p mtal health and ed f or Previo f alternatives plat of drug	for both Te product, plea psychosoci us Modic ad drugs are es)	see provide startial function. EMPORE d/or non-drug M Dosage	t date & objective ev	condition:	r.		
Nagnosis for Gender Dys Reason for u No alternati I the patient If applicable Section 5 a) Please;	r which the drug sphoria ass over formular ive on formula is currently takin is improved mo — Current at provide details o Name dicate of currently	is requested: ry alternatives: ry, needs EAP f rg the requested p mtal health and ed f or Previo f alternatives plat of drug	for both Te product, plan psychosoci us Medic ed drugs an en) current previous	see provide startial function. EMPORE d/or non-drug M Dosage	t date & objective ev	condition:	r.		
Nagnosis for Gender Dys Reason for u No alternati I the patient If applicable Section 5 a) Please;	r which the drug sphoria ass over formular ive on formula is currently takin is improved mo — Current at provide details o Name dicate of currently	is requested: ry alternatives: ry, needs EAP f rg the requested p mtal health and ad f or Previo f alternatives plat of drug	for both Te- product, plan psychosoci- us Medica ad drugs an en) current previous	ase provide starial function. 8410:13 d/or non-drug M Desage	t date & objective ev	condition:	r.		
Nagnosis for Gender Dys Reason for u No alternati I the patient If applicable Section 5 a) Please;	r which the drug sphoria ass over formular ive on formula is currently takin is improved mo — Current at provide details o Name dicate of currently	is requested: ry alternatives: ry, needs EAP f rg the requested p mtal health and ad f or Previo f alternatives plat of drug	for both Te product, plan psychosoci us Medic ad drugs an eni current previous current previous	ase provide starial function. 8410:13 d/or non-drug M Desage	t date & objective ev	condition:	r.		
Nagnosis for Gender Dys Reason for u No alternati I the patient If applicable Section 5 a) Please;	r which the drug sphoria ass over formular ive on formula is currently takin is improved mo — Current at provide details o Name dicate of currently	is requested: ry alternatives: ry, needs EAP f rg the requested p mtal health and ad f or Previo f alternatives plat of drug	for both Te product, plan psychosoci us Medic ed drugs an en) ument previous current previous current	see provide starial function. Billogs d'or non-drug th Dossage	t date & objective ev	condition:	r.		
Nagnosis for Gender Dys Reason for u No alternati I the patient If applicable Section 5 a) Please;	r which the drug sphoria ass over formular ive on formula is currently takin is improved mo — Current at provide details o Name dicate of currently	is requested: ry alternatives: ry, needs EAP f rg the requested p mtal health and ad f or Previo f alternatives plat of drug	for both Te product, plan psychosoci and drugs are con- current previous current previous current previous	see provide starial function. Billogs d'or non-drug th Dossage	t date & objective ev	condition:	r.		
Nagnosis for Gender Dys Reason for u No alternati I the patient If applicable Section 5 a) Please;	r which the drug sphoria ass over formular ive on formula is currently takin is improved mo — Current at provide details o Name dicate of currently	is requested: ry alternatives: ry, needs EAP f rg the requested p mtal health and ad f or Previo f alternatives plat of drug	for both Te product, plan psychosocia and drugs and current previous current previous current previous current	see provide staried function. BHOSTS d/or nov-drug M Dosage	t date & objective ev	condition:	r.		
Diagnosis for Gender Dys Reason for u No alternat If the patient of applicable Section 5 (in:	r which the drug sphoria is cover formula is currently takin is improved me - Current er provide details o higher A/A	is requested: ry afternatives: ry, needs EAP f g the requested p mtal health and of f or Previo f alternatives plat of drug or previously ref [[[[[[[[[[[[[[[[[[for both Te- product, ples psychosoci us Medic ad drugs an oni current previous current previous current previous current previous	see provide staried function. aktions dornarding the Dasage	t date & objective ev	condition:	r.		
Diagnosis for Gender Dys Reason for u No alternat If the patient of applicable Section 5 (in:	r which the drug sphoria is cover formula is currently takin is improved me - Current er provide details o higher A/A	is requested: ry alternatives: ry, needs EAP f rg the requested p mtal health and ad f or Previo f alternatives plat of drug	for both Te- product, ples psychosoci us Medic ad drugs an oni current previous current previous current previous current previous	see provide staried function. aktions dornarding the Dasage	t date & objective ev	condition:	r.		
Diagnosis for Gender Dys Reason for u No alternat If the patient of applicable Section 5 (in:	r which the drug sphoria is cover formula is currently takin is improved me - Current er provide details o higher A/A	is requested: ry afternatives: ry, needs EAP f g the requested p mtal health and of f or Previo f alternatives plat of drug or previously ref [[[[[[[[[[[[[[[[[[for both Te- product, ples psychosoci us Medic ad drugs an oni current previous current previous current previous current previous	see provide staried function. aktions dornarding the Dasage	t date & objective ev	condition:	r.		
Diagnosis for Gender Dys Reason for u No alternat If the patient of applicable Section 5 (in:	r which the drug sphoria is cover formula is currently takin is improved me - Current er provide details o higher A/A	is requested: ry afternatives: ry, needs EAP f g the requested p mtal health and of f or Previo f alternatives plat of drug or previously ref [[[[[[[[[[[[[[[[[[for both Te- product, ples psychosoci us Medic ad drugs an oni current previous current previous current previous current previous	see provide staried function. aktions dornarding the Dasage	t date & objective ev	condition:	r.		
Nagnosis for Gender Dys Reason for u No alternat f the patent of applicable Sciellon 5 a) Please ; (inc	r which the drug sphoria is cover formula is currently takin is improved me - Current er provide details o higher A/A	is requested: ry alternatives: ry, needs EAP if rg the requested p mital health and ad / or Previo f alternatives (list of or previously res companies of the previously rese companies of the previously rese companies of the previously reserved.	for both Te- product, ples psychosoci us Medic ad drugs an oni current previous current previous current previous current previous	see provide staried function. aktions dornarding the Dasage	t date & objective ev	condition:	r.		
Nagnosis for icender Dys Season for us No alternati the patient f applicable Section 5 (inc. (inc. b) Provide Section 6 Please provide Section 6 Section 7 Section 8	r which the drug sphoria size over formula is currently takin c improved me - Current approvide details o N/A N/A s patient's conco	is requested: ry alternatives: ry, needs EAP if g the requested p mtal health and of I or Previo f alternatives plan of drug or previously tel c milant drug thera formation licel data (e.g. col	for both Te product, pleased psychosoci us Medic ad drugs an en) current previous current previous current previous previous current previous previous current previous	see provide staried function. SEIOSS Office non-drug M Dosege or conditions:	t date & objective ev	condition: P Reason(s)	r.		
Nagnosis for Gender Dys Reason for un No alternat I the patient of applicable Section 5 (inc. (inc.) Provide b) Provide Section 6 Please provide Please provide Please	r which the drug sphoria size over formula is currently takin c improved me - Current approvide details o N/A N/A s patient's conco	is requested: ry alternatives: ry, needs EAP if rig the requested p initial health and ad i or Previo f alternatives plat of drug or previously tes c mitiant drug thera	for both Te product, pleased psychosoci us Medic ad drugs an en) current previous current previous current previous previous current previous previous current previous	see provide staried function. SEIOSS Office non-drug M Dosege or conditions:	t data & objective ev herspy) tried for this Approximate timetrame of the	condition: P Reason(s)	r.		
Nagrosis for icender Dys Season for use to No alternatifithe patient of applicable Section 5 of Please provide Section 5 Please provide	r which the drug sphoria sis over formula is currently takin e: improved me - Current ap provide details o Name cloate of currently N/A patient's conco - Clinical in ide relevant med anagement an on this form is on	is requested: ry alternatives: ry, needs EAP if g the requested p mital health and ad / or Previo f alternatives (list of or previously res construction of the recursion of the recursio	for both Teleproduct, pleased of the Medical drugs are entitioned of the medical previous current previous current previous previ	see provide starios function. Billoss d'or non-drug M Dosage Dosage r conditions: r conditions:	t date & objective evi- tenspyl tried for this i Approximate simetrame of the	condition: Prapy Reason(s) aboratory results): Act 2004, S.O. 2004.	subsy formulae		


Other resources:

- World Professional Association for Transgender Health (WPATH), <u>www.wpath.org</u>
- Canadian Professional Association for Transgender Health (CPATH), www.cpath.ca
- UCSF Centre of Excellence for Transgender Health, <u>www.transhealth.ucsf.edu</u>
- Trans Care BC, http://www.phsa.ca/transcarebc
- Rainbow Health Ontario Trans Health Mentorship call (https://www.rainbowhealthontario. ca/trans-health/#mentorship)
- E-consult services: Ontario Telemedicine Network (OTN) https://otnhub.ca

REFERRALS: WHERE TO REFER



https://www.rainbowhealthontario.ca/lgbt2sq-health/service-provider-directory/



APPLYING FOR MOH COVERED GENDER AFFIRMING SURGERY

- Ontario funds two types of surgeries: chest (top) and genital (bottom)
- To qualify for funding:
 - be assessed and recommended for surgery by either one or two healthcare providers
 - have a referral for surgery completed and submitted to the MOHLTC
 - have the surgery approved by the Ministry of Health and Long-Term Care before the surgery takes place

https://forms.mgcs.gov.on.ca/en/dataset/5041-77

Resources

Tools



Links to resources shared today will be sent to participants following the session.

Tools and Resources

Resource	Type	Link
Rainbow Health Ontario – Trans Mentorship Call	Resource	Trans Health Knowledge Base Rainbow Health Ontario
World Professional Association for Transgender Health	Resource	WPATH World Professional Association for Transgender Health
UCSF Centre of Excellence for Transgender Health	Resource	Gender Affirming Health Program (ucsf.edu)
Canadian Professional Association for Transgender Health	Resource	<u>cpath.ca/en/</u>
Trans Care BC	Resource	Home Trans Care BC
E-consult services: Ontario Telemedicine Network (OTN	Resource	Home Page - OTNhub

Resources

Education



Links to resources shared today will be sent to participants following the session.

Practising Well CoP – Self Learning Program

The Practising Well CoP is now certified for self learning credits!


Earn **1-credit-per-hour** for reviewing the recording and resources from **past CoP sessions**. The self learning program is certified for up to 50 Mainpro+ credits.



Learn More and Participate

Peer Connect

Enabling you to connect, share and learn from your fellow family physicians.





Mentorship Program - Connect with a Peer Guide!

An opportunity to partner with another family physician, **one-to-one or in a small group**, for support as you **explore clinical complexity and increase your confidence** caring for patients with mental health challenges, substance use, and chronic pain. A focus can be on your well-being as you engage in this challenging work.





Resources

Supports



Resources

Supports



OMA Physician Health Program https://php.oma.org

Centre for Addiction and Mental Health Health Care Provider (HCP) Resource Site

http://www.camh.ca/covid19hcw

CMA Wellness Hub

https://www.cma.ca/physician-wellnesshub



- PARO 24/7 Helpline for Residents, Family Members, Medical Students
- 1-866-HELP-DOC



- https://www.ontario.ca/#support-health-care-worker
 - Self-led / With peers / Talk to a clinician
- •Ontario Shores Centre for Mental Health Sciences, Whitby
- •St. Joseph's Healthcare, Hamilton
- •The Royal Ottawa Mental Health Centre, Ottawa
- •Waypoint Centre for Mental Health Care, Penetanguishene
- •Centre for Addictions and Mental Health (CAMH), Toronto



- **ECHO Coping with COVID**
 - for health providers (educational credits)
 - Fridays 2-3pm EST

https://camh.echoontario.ca/echo-coping-with-covid/

Support for you and those you care about.

Upcoming Community of Practice

Preventing burnout: Boundary setting strategies for family doctors with Dr. Rupa Patel and Dr. Mary Rowland

DATE CHANGE



July 31, 2024 8:00am – 9:00am

Register Now

practisingwell@ocfp.on.ca

